Analyst Price Target is $11.00
▲ +101.83% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Monte Rosa Therapeutics in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 101.83% upside from the last price of $5.45.
Current Consensus is
Moderate Buy
The current consensus among 3 contributing investment analysts is to moderate buy stock in Monte Rosa Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Read More